Restore substrate, repair the membrane, clear the static.
You don't optimize NAD+ in Phase 1. You flood it. The cell has been running on depleted intracellular pools for years — sometimes decades — and the salvage pathway is too slow to catch up on its own. Phase 1 is a controlled four-week saturation: push raw NAD+ in, block what's degrading it, repair the membrane it lives on, and bypass the electron transport bottlenecks that are wasting whatever ATP you do manage to make. Everything in Phase 2 — sirtuin reactivation, mitochondrial biogenesis, sustained energy — depends on whether Phase 1 actually moved the needle on cellular substrate.
What's actually happening at the cellular level
NAD+ collapses with age and stress because the cell loses the race between supply and demand. The NAD+ salvage pathway recycles nicotinamide back into usable NAD+, but a methyltransferase enzyme called NNMT siphons nicotinamide off the salvage line and methylates it for excretion. As NNMT activity rises (it rises with age, obesity, inflammation), more substrate exits the system permanently. You can pour NMN in the top end indefinitely, but if NNMT is wide open at the bottom, you're filling a leaky bucket.
This is the push-pull model the practitioner corpus has converged on. NMN supplies the precursor (push). 5-Amino-1MQ blocks NNMT from degrading the precursor (pull). Run together, the dual-pathway approach achieves higher intracellular NAD+ levels than either compound alone — and according to the practitioner consensus, outperforms IV NAD+ drips because IV NAD+ floods extracellular space without addressing the intracellular leak.
The injectable-vs-oral NAD+ debate is real, and the corpus is split with a tilt toward a specific answer: injected NAD+ is almost certainly degraded back to NR and NMN before intracellular nicotinamide riboside kinases can use it. Direct NAD+ injection works, but it works because it's getting cleaved into precursors anyway. The push-pull stack achieves the same intracellular endpoint at a fraction of the cost and without the IV chair time.
Then there's the membrane itself. Even saturated NAD+ pools don't restore energy if the electron transport chain is leaking. Cardiolipin — the signature lipid of the inner mitochondrial membrane — holds ETC complexes (especially III and IV) in their working geometry. Damaged cardiolipin = misaligned complexes = electron leakage = ROS production at the source. SS-31 (Elamipretide) binds cardiolipin selectively and stabilizes the membrane, restoring complex alignment and cutting ROS off at the source rather than scavenging it downstream.
Finally, Methylene Blue sits as the electron bypass. Where the ETC has bottlenecks at damaged intermediate complexes, MB accepts electrons directly from NADH at Complex I and shuttles them past the damage straight to Complex IV. ATP gets made even when the chain is broken. Cardiolipin repair (SS-31) is the fix; methylene blue is the workaround that keeps energy flowing while the fix takes hold.
The Phase 1 stack (Weeks 1-4)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| NMN | 500 mcg–1 mg/day | SubQ | Daily, 10–20 day loading block | 🟢 Expert | The "push" — supplies precursor. Inject AM, abdomen-near. Substrate loading dose for longevity stack. |
| 5-Amino-1MQ | 50–100 mg/day | Oral | Daily, AM | 🟢 Expert | The "pull" — blocks NNMT degradation of NAD+. Run for full 4 weeks. |
| NAD+ (subcutaneous) | 100–200 mg | SubQ (insulin syringe) | 2–3x/week, Weeks 1–2 only | 🟣 Experimental | The "load." Substrate confirms SubQ NAD+ uses an insulin syringe into abdominal fat. Lower dose than IV but tolerable without chair time. Drop after Week 2 once push-pull stack is active. |
| SS-31 (Elamipretide) | 0.01–0.25 mg/kg/day | SubQ | Daily | 🟣 Experimental | Cardiolipin stabilization. Substrate cites 40 mg/day in mitochondrial myopathy trials; for Phase 1 reset use weight-based low end. |
| Methylene Blue | 0.5 mg | Oral | Daily, AM | 🟢 Expert | Start at 0.5 mg for 5 days. Only escalate to 1 mg if no noticeable cognitive/energy effect. Never exceed 1 mg without supervision. Higher doses flip dose-response from beneficial to harmful. Cycling is mandatory — 5 days on, 2 off, or take weekends off. |
| NAD+ IV (optional accelerator) | 500–750 mg | IV drip (1–1.5 hr) | 2–4 sessions in Week 1 only | 🔵 Clinical | The substrate-documented "loading" approach — historically 10 straight days at 3,000 mg was the legacy Mexico protocol, but practitioner consensus has settled on 750 mg as the loading dose with 2–4 sessions front-loaded. Most users feel the benefit fade at 3–4 weeks, which is exactly when Phase 2 begins. Skip if cost-prohibitive — the SubQ + push-pull stack reaches the same intracellular endpoint. |
Two protocol-execution notes the corpus is explicit about
Caffeine before any NAD+ infusion or SubQ shot. Caffeine blocks adenosine receptors and reduces the sluggish, uncomfortable "wrung-out" sensation that derails compliance with NAD+ administration. This is practitioner-standard, not a hack.
The flushing reaction is the dose ceiling. When NAD+ is pushed too fast — IV drip rate too quick, SubQ dose too large — you get a characteristic flushing, chest tightness, and gut discomfort. This is the marker that you've found the tolerance edge. Slow the drip or split the SubQ dose. Do not power through. The sweet spot is the dose people actually tolerate, not the dose that looks impressive on paper.
What you should feel (week-by-week)
- Week 1: Initial NAD+ load is uncomfortable. Flushing on injection day. Sleep may be lighter for the first 3–4 nights. Methylene blue produces a noticeable cognitive lift within 60–90 minutes of dosing — clearer thinking, less mental fog. If you don't feel MB at 0.5 mg by Day 5, escalate to 1 mg.
- Week 2: SubQ NAD+ injections become routine. Energy floor lifts — the afternoon crash softens. NMN injections become a non-event. The push-pull stack is now established; you can drop the most expensive component (IV NAD+) and let the daily SubQ + NMN + 5-Amino-1MQ do the work.
- Week 3: Sustained morning energy without caffeine dependence. Recovery from training improves noticeably. This is the SS-31 window — cardiolipin repair is a slow process, but by Week 3 the ROS-driven inflammation signature (gut sensitivity, low-grade joint ache, sleep fragility) typically softens.
- Week 4: Stable baseline. Energy is no longer a thought. This is the marker that Phase 1 worked and Phase 2 (sirtuin activation, biogenesis, MOTS-c) is ready to layer on top.
What's NOT happening yet
- You are not regrowing mitochondria. That's Phase 2 (MOTS-c, sustained NAD+). Phase 1 saturates substrate and stabilizes the membrane on the mitochondria you already have.
- You are not reversing biological age markers. Methylation clocks, telomere data, glycan age — none of these shift in 4 weeks. They shift over 6–12 months of sustained protocol.
- You are not seeing visible body composition changes. 5-Amino-1MQ has a lipolytic side effect, but it's overshadowed in Phase 1 by the NAD+ saturation. Fat loss signal emerges in Phase 2.
- You are not "done" with NAD+. The substrate is explicit: users come back at 3–4 weeks asking for a re-up because the loaded NAD+ pools deplete. The Phase 2 stack (NMN sustained, MOTS-c, cycled MB) is what holds the gain. Stopping at Week 4 means losing it by Week 7.
- You should not chase the flush. Bigger doses are not better. The dose-response curve on NAD+ administration is bell-shaped, and the curve on methylene blue is steeply bell-shaped. The substrate is consistent: more is worse past the sweet spot.
The practitioner corpus describes this loading rhythm consistently across mentors — track your morning energy, sleep latency, and afternoon crash daily for the four weeks, and the response curve will tell you whether to escalate, hold, or adjust before Phase 2.